Oliceridine (Olinvyk): A Comprehensive Pharmacological and Clinical Monograph on the First-in-Class G Protein-Biased Opioid Agonist

Section 1: Executive Summary

Oliceridine is a novel, synthetic, intravenously administered opioid agonist approved by the U.S. Food and Drug Administration (FDA) for the management of acute pain in adults that is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.[1] Marketed under the brand name Olinvyk, it is classified as a Schedule II controlled substance, reflecting its potential for abuse and dependence.[1] Oliceridine represents the first-in-class G protein-biased agonist at the μ-opioid receptor (MOR). This mechanism is designed to preferentially activate the G protein-coupled signaling pathway, which is primarily responsible for analgesia, while minimizing the recruitment and activation of the β-arrestin 2 pathway, a cascade implicated in many of the hallmark adverse effects of conventional opioids, including respiratory depression and gastrointestinal dysfunction.[4]

The clinical development program for oliceridine demonstrated analgesic efficacy that was superior to placebo and non-inferior to morphine in postoperative pain models following both hard tissue (bunionectomy) and soft tissue (abdominoplasty) surgeries.[7] The most pronounced clinical advantage observed in these pivotal trials was a statistically significant improvement in gastrointestinal tolerability, with patients receiving oliceridine experiencing lower rates of nausea and vomiting and requiring less rescue antiemetic medication compared to those treated with morphine at equianalgesic doses.[9]

However, the anticipated clear and significant advantage in respiratory safety was not definitively established in the pre-specified analyses of the Phase III registration trials; the difference between oliceridine and morphine on the composite respiratory safety burden endpoint did not achieve statistical significance.[7] Subsequent post-hoc and retrospective analyses suggest a more favorable respiratory profile, though these findings require prospective confirmation.[12] Furthermore, human abuse potential studies indicate that oliceridine possesses a pharmacological profile and abuse liability comparable to equianalgesic doses of morphine.[3]

Reflecting a careful balance of its benefits and risks, particularly a potential for QTc interval prolongation at higher exposures, the use of oliceridine is subject to critical restrictions. It is indicated only for short-term use in controlled clinical settings and is governed by a maximum recommended cumulative daily dose of 27 mg.[14] Oliceridine is thus positioned not as a universal replacement for conventional opioids, but as a specialized therapeutic option within the acute pain armamentarium, offering a distinct risk-benefit profile that may be particularly advantageous for patients at high risk for postoperative nausea and vomiting.

Section 2: Drug Identification and Physicochemical Characteristics

2.1 Nomenclature and Identifiers

Oliceridine is a small molecule drug developed by Trevena, Inc., and was previously known by the developmental code TRV-130.[16] Upon receiving regulatory approval, it was assigned the brand name Olinvyk, having been referred to as Olinvo during its later stages of development.[18] For precise identification across chemical, regulatory, and biomedical databases, oliceridine is cataloged under numerous unique identifiers, which are consolidated in Table 1.

Table 1: Oliceridine Identifiers and Chemical Properties

Identifier Type	Value	Source Database(s)
DrugBank ID	DB14881	DrugBank 1
CAS Number	1401028-24-7	PubChem, ChEMBL 1
UNII	MCN858TCP0	FDA GSRS 1
DEA Code Number	9245	DEA 1
PubChem CID	66553195	PubChem 14
ChEMBL ID	CHEMBL2443262	ChEMBL 14
KEGG ID	D11214	KEGG 1
IUPAC Name	N-[(3-methoxythiophen-2-yl)methyl]-2-decan-9-yl]ethanamine	PubChem 1

2.2 Molecular Structure and Physicochemical Properties

Oliceridine possesses the molecular formula C22​H30​N2​O2​S and a molecular weight of approximately 386.56 g/mol.[1] Its complex chemical structure is unambiguously defined by standardized chemical notations. The International Union of Pure and Applied Chemistry (IUPAC) name is N-[(3-methoxythiophen-2-yl)methyl]-2-decan-9-yl]ethanamine, which describes the specific arrangement of its thiophene, pyridine, and spirocyclic moieties.[1]

For computational and cheminformatic applications, its structure is represented by the following:

• SMILES (Simplified Molecular Input Line Entry System): COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4 [1]
• InChI (International Chemical Identifier): InChI=1S/C22H30N2O2S/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3/t21-/m1/s1 [1]
• InChIKey: DMNOVGJWPASQDL-OAQYLSRUSA-N [1]

Calculated physicochemical properties provide insight into its drug-like characteristics. With a calculated partition coefficient (AlogP) of 4.69 and a topological polar surface area (TPSA) of 43.38 A˚2, oliceridine is a lipophilic molecule capable of crossing biological membranes.[16] It possesses one hydrogen bond donor and five hydrogen bond acceptors (four by Lipinski criteria), seven rotatable bonds, and two aromatic rings.[16] These properties are consistent with Lipinski's Rule of Five, with zero violations reported, indicating favorable oral bioavailability characteristics, although the drug is formulated for intravenous use only.[16] As a base with a predicted basic pKa of approximately 9.12, it exists primarily in its protonated, cationic form at physiological pH.[16]

Section 3: Mechanism of Action and Clinical Pharmacology

3.1 The μ-Opioid Receptor Signaling Cascade

The pharmacological actions of oliceridine, like all opioid analgesics, are mediated through agonism of the μ-opioid receptor (MOR), a member of the G protein-coupled receptor (GPCR) superfamily.[23] Upon agonist binding, the MOR undergoes a conformational change that triggers two distinct intracellular signaling cascades.

The canonical pathway, responsible for analgesia, involves the coupling and activation of inhibitory G proteins (Gi/o).[23] This activation leads to the dissociation of the G protein into its Gα and Gβγ subunits. The Gα subunit inhibits the enzyme adenylyl cyclase, reducing intracellular levels of cyclic adenosine monophosphate (cAMP). Concurrently, the Gβγ subunit directly modulates ion channels, leading to the opening of G protein-coupled inwardly-rectifying potassium (GIRK) channels and the inhibition of voltage-gated calcium channels. The combined effect of these actions is hyperpolarization of the neuronal membrane and reduced neurotransmitter release, which ultimately dampens the transmission of nociceptive signals in the central nervous system.[5]

A second, distinct pathway is initiated following receptor phosphorylation by GPCR kinases (GRKs). This phosphorylation promotes the binding of an intracellular protein, β-arrestin 2, to the receptor.[23] The recruitment of β-arrestin 2 serves multiple functions: it sterically hinders further G protein coupling, leading to desensitization of the analgesic signal; it facilitates receptor internalization (endocytosis), removing it from the cell surface; and it acts as a scaffold to initiate its own unique signaling cascades.[5] The β-arrestin pathway has been mechanistically linked to many of the dose-limiting adverse effects of conventional opioids, including respiratory depression, constipation, and the development of tolerance.[6]

3.2 Oliceridine's Functional Selectivity ("Biased Agonism")

The central innovation in the design of oliceridine is its property of functional selectivity, also known as "biased agonism".[1] Oliceridine binds to the MOR and preferentially activates the G protein signaling pathway while only minimally recruiting and activating the β-arrestin 2 pathway.[4] In vitro studies demonstrate that oliceridine elicits robust G protein signaling with a potency and efficacy comparable to that of morphine, but with substantially less β-arrestin 2 recruitment and subsequent receptor internalization.[14] This selective activation is hypothesized to uncouple the desired analgesic effects from the adverse effects mediated by β-arrestin, thereby creating a wider therapeutic window.[1]

It is important to acknowledge an ongoing pharmacological debate regarding the precise nature of this selectivity. Some evidence suggests that oliceridine's observed effects may be attributable to its behavior as a partial agonist with low intrinsic efficacy, rather than true G protein pathway-specific bias.[14] In this model, oliceridine's lower maximal stimulation of the receptor is sufficient to fully engage the highly amplified G protein pathway but is insufficient to trigger the threshold of receptor phosphorylation required for robust β-arrestin recruitment. While the "biased agonist" paradigm drove the drug's development, its clinical profile may be functionally indistinguishable from that of a partial agonist.[27] Regardless of the precise molecular mechanism, the intended and observed clinical outcome is a pharmacological profile that, at equianalgesic concentrations, may be associated with a reduced burden of certain adverse events compared to conventional full MOR agonists like morphine.

3.3 Pharmacokinetics (ADME)

The pharmacokinetic profile of oliceridine is characterized by its intravenous route of administration, rapid distribution, hepatic metabolism into inactive compounds, and a relatively short half-life, befitting its role in managing acute pain. A summary of key parameters is provided in Table 2.

• Absorption: As oliceridine is administered exclusively via the intravenous route, bioavailability is 100%, and its onset of action is rapid. Following single IV injections in healthy volunteers, maximum plasma concentrations (Cmax) and area under the curve (AUC) were shown to be dose-proportional.[24] Clinical studies report perceptible pain relief within minutes of administration.[7]
• Distribution: Oliceridine distributes from the plasma into the tissues, with a mean steady-state volume of distribution (Vd​) ranging from 90 to 126 L.[7] It is approximately 77% bound to plasma proteins.[7]
• Metabolism: The drug undergoes extensive hepatic metabolism. In vitro studies have identified cytochrome P450 enzymes CYP3A4 and CYP2D6 as the primary contributors to its metabolism, with minor involvement from CYP2C9 and CYP2C19.[7] Metabolic pathways include N-dealkylation, glucuronidation, and dehydrogenation.[24] A critical feature of oliceridine's pharmacology is that none of its known metabolites are pharmacologically active.[24] This represents a significant departure from morphine, which is metabolized to the potent analgesic morphine-6-glucuronide and the potentially neuroexcitatory morphine-3-glucuronide. The absence of active metabolites simplifies oliceridine's pharmacokinetic profile and eliminates concerns about their accumulation, particularly in patients with altered renal function.
• Excretion: Oliceridine and its metabolites are eliminated from the body through both renal and fecal routes. Approximately 70% of the administered dose is recovered in the urine, with a small fraction (0.97% to 6.75%) excreted as the unchanged parent drug. The remaining 30% is eliminated in the feces.[7] The parent compound has a short elimination half-life ( t1/2​) of 1.3 to 3 hours, consistent with its rapid clearance rates of 34 to 59.6 L/h.[24] In contrast, the inactive metabolites possess a substantially longer half-life of approximately 44 hours.[24]

Table 2: Key Pharmacokinetic Parameters of Oliceridine

Parameter	Value	Clinical Implication
Tmax (IV)	< 5 minutes	Rapid onset of analgesia suitable for acute pain.
Volume of Distribution (Vd​)	90–126 L	Moderate tissue distribution.
Protein Binding	~77%	Moderate binding to plasma proteins.
Half-life (t1/2​) - Parent	1.3–3 hours	Short duration of action necessitates frequent dosing (e.g., PCA) for sustained analgesia.
Half-life (t1/2​) - Metabolites	~44 hours	Metabolites are inactive, so their long half-life is not clinically significant.
Clearance	34–59.6 L/h	Rapid clearance from the body.
Primary Metabolizing Enzymes	CYP3A4, CYP2D6	Potential for drug-drug interactions with inhibitors or inducers of these enzymes.
Route of Elimination	~70% Renal, ~30% Fecal	Predominantly renal excretion of inactive metabolites.

Section 4: Regulatory History and Approved Indications

4.1 FDA Approval Timeline and Indication

The regulatory pathway for oliceridine was notable for its initial challenges, which ultimately shaped the drug's final approved labeling and restrictions. Following the submission of a New Drug Application (NDA) by Trevena, Inc. in late 2017, the FDA's Anesthetic and Analgesic Drug Products Advisory Committee convened in October 2018.[19] The committee voted narrowly, 8 to 7, against recommending approval, citing concerns that the demonstrated benefits of oliceridine did not outweigh its risks, with specific attention given to its potential for QTc interval prolongation.[15] Subsequently, in November 2018, the FDA issued a Complete Response Letter, formally declining the application.[19]

After conducting additional safety analyses and engaging in further discussions with the agency, Trevena resubmitted the NDA in February 2020.[19] This revised application included a key risk mitigation strategy: a maximum recommended daily dose. On August 7, 2020, the FDA granted approval for oliceridine.[19] The approved indication is for the "management of acute pain in adults severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate".[1] This indication positions oliceridine as a second-line agent for a specific patient population in a specific clinical context.

4.2 Usage Restrictions and Controlled Substance Scheduling

The approval of oliceridine is accompanied by stringent limitations on its use, designed to ensure patient safety. It is indicated exclusively for short-term intravenous administration and must be used only in hospitals or other controlled clinical settings, such as during inpatient or outpatient procedures.[14] The drug is explicitly not approved for at-home or outpatient prescription use.[14]

A central element of its risk management is the maximum recommended cumulative daily dose of 27 mg.[14] This dose cap was established to mitigate the risk of QTc interval prolongation, the key safety concern that initially hindered its approval.[15] The imposition of this daily limit fundamentally defines oliceridine's clinical role as an agent for acute, short-duration pain management where total drug exposure is carefully controlled.

Reflecting its mechanism as a potent MOR agonist with demonstrated abuse potential comparable to other opioids, the U.S. Drug Enforcement Administration (DEA) has placed oliceridine in Schedule II of the Controlled Substances Act.[1] This classification imposes the strictest level of control for a medically approved substance, mandating specific prescribing, dispensing, and record-keeping practices to prevent diversion and misuse.

Section 5: Clinical Efficacy in the Management of Acute Pain

5.1 Overview of the Phase III Clinical Development Program

The efficacy and safety of oliceridine were primarily established in a robust Phase III program involving over 1,500 patients.[29] The program was anchored by two pivotal, randomized, double-blind, placebo- and active-controlled trials:

• APOLLO-1 (NCT02815709): This study evaluated oliceridine in patients with moderate-to-severe acute pain following a hard tissue surgical model (bunionectomy) over a 48-hour period.[7]
• APOLLO-2 (NCT02862024): This study assessed oliceridine in a soft tissue surgical model (abdominoplasty) over a 24-hour period.[6]

In both trials, patients were randomized to receive placebo, morphine, or one of three oliceridine dosing regimens administered via patient-controlled analgesia (PCA).[8] The primary efficacy endpoint was the responder rate, a categorical outcome defined as a patient achieving at least a 30% improvement from baseline in the time-weighted Sum of Pain Intensity Differences (SPID) without early discontinuation.[31] The program also included

ATHENA (NCT02656875), a large, open-label safety study that enrolled a broad population of 768 patients with moderate-to-severe acute pain from various surgical procedures or medical conditions, including elderly, obese, and medically complex patients, providing data on real-world use.[7]

5.2 Efficacy Results from Pivotal Trials (APOLLO-1 & APOLLO-2)

The results from the APOLLO trials consistently demonstrated the analgesic efficacy of oliceridine.

• Superiority to Placebo: In both the bunionectomy and abdominoplasty studies, all three oliceridine PCA demand dose regimens (0.1 mg, 0.35 mg, and 0.5 mg) resulted in statistically significantly higher responder rates compared to placebo.[7] This established that oliceridine provides effective analgesia for moderate-to-severe postoperative pain. For instance, in APOLLO-2, responder rates for the oliceridine regimens ranged from 61.0% to 76.3%, compared to 45.7% for placebo ( p<0.05 for all comparisons).[8]
• Non-Inferiority to Morphine: Exploratory and non-inferiority analyses were conducted to compare the efficacy of oliceridine to the active comparator, morphine (1 mg PCA demand dose). The two higher-dose oliceridine regimens (0.35 mg and 0.5 mg demand doses) were found to be non-inferior, or equianalgesic, to the 1 mg morphine regimen.[7] This finding is crucial as it establishes a clinical potency relationship and provides the basis for comparing the safety profiles of the two drugs at therapeutically equivalent doses.
• Onset of Action: Oliceridine demonstrated a rapid onset of analgesia. The median time to perceptible pain relief was reported as 6 minutes, with meaningful pain relief achieved in approximately 12 minutes, which was comparable to or, in some analyses, faster than morphine.[7]

5.3 Real-World Evidence from the ATHENA Study

The ATHENA open-label safety study provided supportive evidence of oliceridine's effectiveness in a more heterogeneous patient population than that included in the tightly controlled pivotal trials.[7] This study included patients with various comorbidities such as diabetes and sleep apnea, as well as elderly and obese individuals.[29] In this real-world setting, oliceridine, administered via clinician bolus, PCA, or a combination, was effective in providing rapid and sustained reduction in pain intensity scores from baseline.[7] The safety profile observed in ATHENA was consistent with the findings from the APOLLO trials, confirming its tolerability across a broad range of patients requiring intravenous opioid therapy.[7]

Section 6: Safety and Tolerability Profile

6.1 Black Box Warnings and Contraindications

As a potent opioid agonist, oliceridine carries an FDA-mandated boxed warning, the most stringent warning for prescription drugs, highlighting several life-threatening risks common to the opioid class.[14]

• Addiction, Abuse, and Misuse: The warning emphasizes that oliceridine exposes users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Healthcare providers are advised to assess each patient's risk prior to prescribing and monitor all patients regularly for the development of these behaviors or conditions.[14]
• Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur. This risk is highest during initiation of therapy or following a dosage increase and is accentuated in elderly, cachectic, or debilitated patients, or those with pre-existing pulmonary disease.[14]
• Neonatal Opioid Withdrawal Syndrome: Prolonged use of oliceridine during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated.[14]
• Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants: The concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., alcohol, sedatives, other narcotics) may result in profound sedation, respiratory depression, coma, and death.[14]

Oliceridine is contraindicated in patients with:

• Significant respiratory depression.[14]
• Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment.[14]
• Known or suspected gastrointestinal obstruction, including paralytic ileus.[14]
• Known hypersensitivity to oliceridine.[14]

6.2 Common and Serious Adverse Events

The overall safety profile of oliceridine is similar to that of other intravenous opioids.[14] In the pivotal clinical trials, the most frequently reported treatment-emergent adverse events (occurring in ≥10% of patients) were nausea, vomiting, dizziness, headache, constipation, pruritus, and hypoxia.[33] The incidence and severity of these adverse events, particularly gastrointestinal and respiratory effects, were generally dose-dependent.[7] Most reported adverse events in the clinical program were of mild or moderate intensity.[7]

6.3 Specific Safety Concerns

• QTc Interval Prolongation: Oliceridine has been demonstrated to cause a dose-dependent prolongation of the QTc interval on the electrocardiogram.[33] This effect was a primary concern during its regulatory review and is the basis for the strict maximum recommended cumulative daily dose of 27 mg. Exceeding this daily dose has not been evaluated and may increase the risk of developing potentially fatal cardiac arrhythmias such as Torsades de Pointes.[15]
• Hepatotoxicity: In clinical trials, oliceridine was associated with a low rate of serum aminotransferase (ALT) elevations (1% to 3%), a frequency similar to that observed with morphine (2.4%).[1] These elevations were generally mild, transient, and not associated with jaundice or clinical symptoms of liver injury. To date, oliceridine has not been linked to instances of clinically apparent drug-induced liver injury.[1]

Section 7: Comparative Assessment: Oliceridine versus Morphine

The clinical development program for oliceridine was designed with morphine as the active comparator, allowing for a direct comparison of efficacy and safety at equianalgesic doses. This comparative analysis is essential for defining oliceridine's potential role in clinical practice.

7.1 Efficacy and Potency

As established in the APOLLO trials, PCA demand doses of 0.35 mg and 0.5 mg of oliceridine were non-inferior to a 1 mg PCA demand dose of morphine for the management of postoperative pain.[7] This suggests an approximate relative potency ratio of 2-3:1 for PCA dosing (i.e., 1 mg of morphine is roughly equianalgesic to 0.35-0.5 mg of oliceridine). While non-inferiority was met, some analyses noted that morphine produced numerically higher response rates or greater pain reduction, though these differences were not statistically significant.[33]

7.2 Respiratory Safety Profile (OIRD)

The foundational hypothesis for oliceridine was that its G protein bias would translate into a significantly improved respiratory safety profile compared to conventional opioids. The preclinical data in animal models strongly supported this premise, suggesting a wider therapeutic window between analgesia and respiratory depression.[12] However, the results from the pivotal Phase III trials presented a more complex picture.

The APOLLO trials utilized a pre-specified secondary endpoint known as the Respiratory Safety Burden (RSB), a composite measure reflecting the cumulative duration of clinically relevant respiratory safety events (e.g., low respiratory rate, low oxygen saturation).[8] While oliceridine demonstrated a dose-dependent increase in RSB, the primary analysis

failed to show a statistically significant difference in RSB between the equianalgesic oliceridine regimens (0.35 mg and 0.5 mg) and the morphine 1 mg regimen.[7] The incidence of individual respiratory events was numerically lower in the oliceridine groups, but the trials may have been underpowered to detect a statistically significant difference for this endpoint.[35]

In contrast, subsequent exploratory, post-hoc analyses of the pooled trial data, as well as retrospective chart review studies, have suggested a more favorable respiratory profile. These analyses have reported a significantly lower incidence of operationally defined opioid-induced respiratory depression (OIRD) in patients treated with oliceridine compared to those treated with morphine or other conventional opioids.[12] While these findings are encouraging and align with the drug's proposed mechanism, they are not as robust as the results from the pre-specified analyses of the registration trials. Therefore, while there is a signal for improved respiratory safety, it was not definitively proven in the pivotal studies.

7.3 Gastrointestinal Tolerability (PONV)

The most consistent and statistically robust advantage of oliceridine over morphine observed in the clinical program is its superior gastrointestinal tolerability profile. Postoperative nausea and vomiting (PONV) are highly prevalent and distressing adverse events that can delay recovery and increase healthcare costs.[25]

Across both APOLLO trials, patients treated with equianalgesic doses of oliceridine experienced significantly lower rates of nausea and vomiting and had a significantly lower requirement for rescue antiemetic medications compared to patients treated with morphine.[7] To quantify this benefit, an exploratory endpoint of "complete GI response"—defined as experiencing no vomiting and requiring no rescue antiemetics—was analyzed. After controlling for the level of analgesia, patients receiving oliceridine had 2 to 3 times higher odds of achieving a complete GI response compared to those receiving morphine (

p<0.05).[9] This clear and clinically meaningful benefit in GI tolerability represents the primary safety differentiator for oliceridine based on the highest level of clinical evidence.

7.4 Abuse Potential and Physical Dependence

Despite the novel mechanism of action, studies designed to evaluate abuse potential have concluded that oliceridine's profile is similar to that of other potent MOR agonists. A human abuse potential study directly comparing intravenous oliceridine to morphine found that equianalgesic doses produced similar subjective ratings on scales such as "Drug Liking," "Take Drug Again," and "Overall Drug Liking".[3] Preclinical studies in animal models of drug self-administration also demonstrated that oliceridine functions as a reinforcer with a potency and effectiveness comparable to that of morphine and oxycodone.[11] These findings strongly indicate that oliceridine retains a high potential for abuse and psychological dependence, fully justifying its placement as a Schedule II controlled substance. The potential for physical dependence is also assumed to be similar to other opioids.

Table 3: Comparative Summary of Oliceridine vs. Morphine in Pivotal Trials (APOLLO-1 & -2)

Endpoint	Oliceridine 0.35 mg PCA	Oliceridine 0.5 mg PCA	Morphine 1.0 mg PCA	Placebo	Key Finding/P-value
Responder Rate	Superior to Placebo	Superior to Placebo	Superior to Placebo	Baseline	Oliceridine regimens were statistically superior to placebo (p<0.05).8
Non-inferiority vs. Morphine	Non-inferior	Non-inferior	-	-	0.35 mg and 0.5 mg oliceridine regimens were non-inferior to morphine.7
Respiratory Safety Burden (RSB)	Numerically Lower	Numerically Lower	Higher	Lower	No statistically significant difference between oliceridine and morphine regimens.7
Incidence of Nausea	Lower	Lower	Higher	Lower	Significantly lower relative risk with oliceridine regimens vs. morphine.8
Incidence of Vomiting	Lower	Lower	Higher	Lower	Significantly lower relative risk with oliceridine regimens vs. morphine.8
Use of Rescue Antiemetics	Lower	Lower	Higher	Lower	Odds ratio for rescue use was significantly lower in all oliceridine groups vs. morphine (p<0.05).11
"Complete GI Response"	Higher	Higher	Lower	Higher	Odds ratio for complete GI response was 2-3 times higher for oliceridine vs. morphine (p<0.05).9

Section 8: Dosing, Administration, and Clinical Recommendations

8.1 Recommended Dosing Regimens

The administration of oliceridine must be individualized based on the severity of pain, patient response, prior analgesic experience, and risk factors for adverse events. It is for intravenous use only and should be administered as part of a multimodal analgesic regimen whenever possible.[32]

• Initial Clinician-Administered Dose: The recommended initial dose is 1.5 mg, administered as an intravenous bolus.[32]
• Patient-Controlled Analgesia (PCA): When administered via PCA, the recommended on-demand dose is 0.35 mg. A 6-minute lockout interval should be used. For some patients, a higher on-demand dose of 0.5 mg may be considered if the potential benefit is judged to outweigh the increased risk of adverse events.[32]
• Clinician-Administered Supplemental Doses: As-needed supplemental doses of 0.75 mg may be administered by a clinician, starting no sooner than 1 hour after the initial dose and no more frequently than once per hour thereafter.[32]
• Maximum Daily Dose: The cumulative daily dose of oliceridine must not exceed 27 mg. If a patient's analgesic needs exceed this limit, an alternative analgesic must be used until oliceridine can be resumed the following day. This limit is critical for mitigating the risk of QTc interval prolongation.[15]

8.2 Management in Special Populations

Dosage adjustments and increased monitoring may be necessary for certain patient populations.

• Geriatric Patients: As with all opioids, dosage selection for elderly patients should be cautious, typically starting at the low end of the dosing range and titrating slowly to effect, with close monitoring for adverse events, particularly respiratory depression.[32]
• Hepatic Impairment: For patients with mild to moderate hepatic impairment, no initial dose adjustment is required, but the interval between supplemental doses may need to be extended. In patients with severe hepatic impairment, oliceridine should be used with caution; a reduction in the initial dose should be considered, and subsequent doses should be administered only after careful clinical reassessment.[32]
• Renal Impairment: No dosage adjustment is required for patients with renal impairment.[32] This is a notable potential advantage over morphine, whose active metabolites can accumulate in patients with renal dysfunction, leading to toxicity.
• CYP2D6 Poor Metabolizers: Patients who are known to be poor metabolizers of the CYP2D6 enzyme may experience higher plasma concentrations of oliceridine. Less frequent dosing may be required in this population, with subsequent doses guided by the patient's clinical response.[32]

8.3 Clinical Placement and Expert Perspective

Oliceridine is a specialized agent, not a first-line replacement for all intravenous opioids. Its clinical profile suggests a specific niche in the management of moderate-to-severe acute pain in the controlled, inpatient setting. Its primary, evidence-backed advantage is a superior gastrointestinal tolerability profile compared to morphine, making it a compelling option for patients at high risk for PONV or for whom PONV could significantly complicate recovery or delay discharge. Its rapid onset of action is also advantageous in the immediate postoperative period.

The pharmacokinetic profile, particularly the lack of active metabolites, makes oliceridine a theoretically safer choice than morphine in patients with renal impairment, as the risk of toxic metabolite accumulation is eliminated. However, clinicians must remain vigilant. The anticipated revolutionary benefit in respiratory safety was not borne out in the pivotal trials, and its abuse potential is equivalent to that of morphine. The strict 27 mg daily dose limit, implemented to manage cardiac risk, firmly restricts its use to short-term scenarios (typically ≤48 hours). Therefore, oliceridine should be used with the same precautions and monitoring as any other potent Schedule II opioid, with its selection guided by a patient-specific assessment of the risks and benefits, particularly the trade-off between improved GI tolerability and the need for careful dose limitation.

Section 9: Conclusion

Oliceridine (Olinvyk) marks an important, albeit incremental, advancement in opioid pharmacology. As the first clinically approved G protein-biased agonist of the μ-opioid receptor, it validates a novel drug design strategy aimed at separating analgesia from opioid-related adverse events. Clinical evidence from its robust development program confirms that it is an effective intravenous analgesic for moderate-to-severe acute pain, with an efficacy non-inferior to that of morphine.

The principal clinical advantage of oliceridine, supported by the highest level of evidence from its registration trials, is its significantly improved gastrointestinal safety profile, manifesting as a lower incidence of postoperative nausea and vomiting compared to morphine at equianalgesic doses. This positions oliceridine as a valuable therapeutic option for specific patient populations where minimizing PONV is a clinical priority. Furthermore, its metabolism into inactive compounds and lack of required dose adjustment in renal impairment offer a clear pharmacokinetic advantage over morphine.

However, the initial promise of a substantially safer opioid has been tempered by the clinical trial results. The hypothesized major improvement in respiratory safety was not statistically confirmed in the primary analyses of pivotal studies, and its abuse liability is comparable to that of conventional opioids. Its use is appropriately restricted to controlled clinical settings and is governed by a strict 27 mg maximum daily dose to mitigate the risk of QTc prolongation.

In conclusion, oliceridine is not a panacea for the opioid crisis nor a universally "safer" opioid. Rather, it is a specialized tool in the perioperative and acute pain armamentarium. Its rational use should be selective, targeted toward short-term (≤48 hours) scenarios in patients who may derive particular benefit from its favorable gastrointestinal and pharmacokinetic profiles. The introduction of oliceridine encourages a more nuanced, mechanism-informed approach to opioid selection, while simultaneously reinforcing the fundamental principles of cautious dosing, vigilant monitoring, and multimodal analgesia that are paramount to the safe and effective management of acute pain.

Works cited

1. Oliceridine | C22H30N2O2S | CID 66553195 - PubChem, accessed August 28, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Oliceridine
2. Oliceridine: First Approval - PubMed, accessed August 28, 2025, https://pubmed.ncbi.nlm.nih.gov/33025536/
3. Oliceridine - FDA, accessed August 28, 2025, https://www.fda.gov/files/advisory%20committees/published/AADPAC-10112018-TrevanaBackgrounder.pdf
4. go.drugbank.com, accessed August 28, 2025, https://go.drugbank.com/drugs/DB14881#:~:text=Oliceridine%20acts%20as%20a%20%22biased,and%20recruitment%20of%20%CE%B2%2Darrestin.
5. What is the mechanism of Oliceridine fumarate? - Patsnap Synapse, accessed August 28, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-oliceridine-fumarate
6. Oliceridine: A Novel Drug for the Management of Moderate to Severe Acute Pain - A Review of Current Evidence - PubMed, accessed August 28, 2025, https://pubmed.ncbi.nlm.nih.gov/33889018/
7. Olinvyk Generic Name: oliceridine Manufacturer: Trevena Drug Class: Analgesic / Central Nervous Syste - WVU School of Pharmacy, accessed August 28, 2025, https://pharmacy.hsc.wvu.edu/media/3352/olinvyk-oliceridine-monograph.pdf
8. APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty - PubMed, accessed August 28, 2025, https://pubmed.ncbi.nlm.nih.gov/31162798/
9. Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials. - Scholars@Duke publication, accessed August 28, 2025, https://scholars.duke.edu/publication/1465419
10. Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory, accessed August 28, 2025, https://d-nb.info/1224266218/34
11. What evidence supports the use of oliceridine for severe pain? | Drug Information Group, accessed August 28, 2025, https://dig.pharmacy.uic.edu/faqs/2020-2/december-2020-faqs/what-evidence-supports-the-use-of-oliceridine-for-severe-pain/
12. Biased Opioid Ligands: Revolution or Evolution? - Frontiers, accessed August 28, 2025, https://www.frontiersin.org/journals/pain-research/articles/10.3389/fpain.2021.722820/full
13. Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis - PubMed, accessed August 28, 2025, https://pubmed.ncbi.nlm.nih.gov/33163127/
14. Oliceridine - Wikipedia, accessed August 28, 2025, https://en.wikipedia.org/wiki/Oliceridine
15. Oliceridine Approved for Management of Acute Pain | ASH Clinical News, accessed August 28, 2025, https://ashpublications.org/ashclinicalnews/news/5251/Oliceridine-Approved-for-Management-of-Acute-Pain
16. Compound: OLICERIDINE (CHEMBL2443262) - ChEMBL - EMBL-EBI, accessed August 28, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL2443262
17. Oliceridine - New Drug Approvals, accessed August 28, 2025, https://newdrugapprovals.org/2016/05/04/oliceridine/
18. TRV 130 | 1401028-24-7 - ChemicalBook, accessed August 28, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB12716393.htm
19. Olinvyk (oliceridine) FDA Approval History - Drugs.com, accessed August 28, 2025, https://www.drugs.com/history/olinvyk.html
20. Oliceridine | 1401028-24-7 | FO180059 - Biosynth, accessed August 28, 2025, https://www.biosynth.com/p/FO180059/1401028-24-7-oliceridine
21. Oliceridine 98% | CAS: 1401028-24-7 | AChemBlock, accessed August 28, 2025, https://www.achemblock.com/m15376-oliceridine.html
22. 3D structure for Oliceridine (DB14881) | DrugBank Online, accessed August 28, 2025, https://go.drugbank.com/structures/small_molecule_drugs/DB14881
23. Oliceridine - NROChemistry, accessed August 28, 2025, https://nrochemistry.com/oliceridine/
24. Oliceridine: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 28, 2025, https://go.drugbank.com/drugs/DB14881
25. Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review - PubMed Central, accessed August 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10040154/
26. Biased versus Partial Agonism in the Search for Safer Opioid Analgesics - MDPI, accessed August 28, 2025, https://www.mdpi.com/1420-3049/25/17/3870
27. Full article: Preclinical discovery and development of oliceridine (Olinvyk®) for the treatment of post-operative pain, accessed August 28, 2025, https://www.tandfonline.com/doi/full/10.1080/17460441.2022.2008903
28. Oliceridine- Opioid of the 21st Century - PMC - PubMed Central, accessed August 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8846232/
29. Trevena Announces FDA Approval of OLINVYK™ (oliceridine) injection, accessed August 28, 2025, https://www.trevena.com/investors/press-releases/detail/234/trevena-announces-fda-approval-of-olinvyk-oliceridine-injection
30. FDA Approves New Opioid for Intravenous Use in Hospitals, Other ..., accessed August 28, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-new-opioid-intravenous-use-hospitals-other-controlled-clinical-settings
31. Full article: A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain - Taylor & Francis Online, accessed August 28, 2025, https://www.tandfonline.com/doi/full/10.1080/14737175.2022.2072731
32. Oliceridine Fumarate Monograph for Professionals - Drugs.com, accessed August 28, 2025, https://www.drugs.com/monograph/oliceridine-fumarate.html
33. Oliceridine - LiverTox - NCBI Bookshelf, accessed August 28, 2025, https://www.ncbi.nlm.nih.gov/books/NBK605806/
34. Cost–effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain, accessed August 28, 2025, https://becarispublishing.com/doi/10.2217/cer-2021-0107
35. Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials - PubMed Central, accessed August 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8586048/
36. Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review - Dove Medical Press, accessed August 28, 2025, https://www.dovepress.com/oliceridine-for-the-management-of-moderate-to-severe-acute-postoperati-peer-reviewed-fulltext-article-DDDT
37. Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials | springermedizin.de, accessed August 28, 2025, https://www.springermedizin.de/oliceridine-exhibits-improved-tolerability-compared-to-morphine-/19546090
38. Overview and Prospects of the Clinical Application of Oliceridine - Dove Medical Press, accessed August 28, 2025, https://www.dovepress.com/overview-and-prospects-of-the-clinical-application-of-oliceridine-peer-reviewed-fulltext-article-DDDT
39. Efficacy and safety of oliceridine treatment in patients with postoperative pain: a systematic review and meta-analysis of randomized controlled trials - PubMed, accessed August 28, 2025, https://pubmed.ncbi.nlm.nih.gov/37171148/
40. Abuse Potential of Biased Mu Opioid Receptor Agonists - PMC, accessed August 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8174448/